Clinical significance of serum p53 antigen in patients with pancreatic carcinomas

Gut

Volumn 40, Issue 5, 1997, Pages 647-653

  Suwa, H ^a   Ohshio, G ^a   Okada, N ^a   Wang, Z ^a   Fukumoto, M ^a   Imamura, T ^a   Imamura, M ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Enzyme linked immunosorbent assay; Immunohistochemistry; p53 protein

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROTEIN P53;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; CYSTADENOCARCINOMA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0030925696     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.5.647     Document Type: Article

References (34)

1. Vogelstein B, Kinzler KW. p53 Function and dysfunction. Cell 1992; 70: 523-6.
2. Levine AJ, Momand J, Finley CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.
3. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 1994; 58: 185-91.
4. Boschman CR, Stryker S, Reddy JK, Rao S. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol 1994; 145: 1291-5.
5. Luo JC, Neugut AI, Garbowski G, Forde KA, Treat M, Smith S, et al. Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett 1995; 91: 235-40.
6. Fontanini G, Bigini D, Vignati S, Calvo S, Mussi A, Lucchi M, et al. Levels of p53 antigen in the serum of non-small cell lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement. Int J Oncol 1994; 5: 553-8.
7. Luo JC, Zehab R, Anttila S, Ridanpaa M, Husgafvel-Pursiainen K, Vainio H, et al. Detection of serum p53 protein in lung cancer patients. J Occup Med 1994; 36: 155-60.
8. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, et al. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076-82.
9. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Lacono C, et al. Pancreatic adenocarcinoma frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-43.
10. Ruggeri B, Zhang S-Y, Caamano J, Dirado M, Flynn SD, Klein-Szanto AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992; 7: 1503-11.
11. Suwa H, Yoshimura T, Yamaguchi N, Kanehira K, Manabe T, Imamura M, et al. K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines. Jpn J Cancer Res 1994; 85: 1005-14.
12. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, et al. K-ras and p53 mutations in pancreatic-cancer: ductal and non-ductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-60.
13. Nakamori S, Yashima K, Murakami Y, Ishikawa O, Ohigashi H, Imaoka S. Association of p53 gene mutation with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995; 86: 174-81.
14. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994; 14: 2477-84.
15. Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T, Uras H, et al. Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 1994; 118: 150-4.
16. Lundin J, Nordling S, von Boguslawsly K, Roberts PJ, Haglund C. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 1996; 53: 104-11.
17. Vojtesek B, Fisher CJ, Barnes DM, Lane DP. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer 1993; 67: 1254-8.
18. Gibson JB, Sobin LH. Histological typing of tumours of the liver, biliary tract, and pancreas. Geneva: World Health Organization, 1978. (WHO, International Histological Classification of Tumours, No 20.)
19. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-602.
20. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunohistochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 1992; 151: 237-44.
21. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against p53 tumor suppressor protein in various cancers. Int J Cancer 1994; 58: 480-7.
22. Laurent-Puig P, Lubin R, Semhoun-Ducloux S, Pelletier G, Fourre C, Ducreux M, et al. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 1995; 36: 455-8.
23. Schlichtholz B, Legros V, Gillet D, Gaillard C, Marty M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52: 6380-4.
24. Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, et al. Serum p53 antibodies as early markers of lung cancer. Nature Med 1995; 1: 701-2.
25. Warshaw AL, Castillo CF. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65.
26. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994; 69: 515-9.
27. Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer 1996; 78: 57-62.
28. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, et al. p53 Mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993; 69: 151-60.
29. Digiuseppe JA, Hruban RH, Goodman SN, Polak M, Van den Berg FM, Allison DC, et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1993; 101: 684-8.
30. Lee CS, Rush M, Charalambous D, Rode J. Immunohistochemical demonstration of the p53 tumour suppressor gene product in cancer of the pancreas and chronic pancreatitis. J Gastroenterol Hepatol 1993; 8: 465-9.
31. Bayever E, Haines K, Iversen PL, Ruddon RW, Pirruccello SJ, Mountjoy CP, et al. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk Lymphoma 1994; 12: 223-31.
32. Bi S, Lanza F, Goldman J. The involvement of 'tumor suppressor' p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res 1994; 54: 582-6.
33. Barton CM, Lemoine NR. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects in p53 expression. Br J Cancer 1995; 71: 429-37.
34. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, et al. p53 Gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54: 5824-30.